Want to see IN:GLAXO full AI Analyst Report?
GLAXO Stock Chart & Stats
₹2513.25
₹36.90(1.47%)
At close: 4:00 PM EDT
₹2513.25
₹36.90(1.47%)
Day’s Range― - ―
52-Week Range₹2,088.00 - ₹3,121.10
Previous CloseN/A
Volume67.92K
Average Volume (3M)3.99K
Market Cap
₹420.73B
Enterprise Value₹359.33B
Total Cash (Recent Filing)₹27.57B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)39.6
Beta0.87
Next Earnings
Nov 03, 2026EPS Estimate
16.5Next Dividend Ex-DateN/A
Dividend Yield2.29%
Share Statistics
EPS (TTM)63.05
Shares Outstanding169,406,040
10 Day Avg. Volume2,257
30 Day Avg. Volume3,992
Financial Highlights & Ratios
PEG Ratio3.20
Price to Book (P/B)17.06
Price to Sales (P/S)10.12
P/FCF Ratio39.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)69.9
Revenue Forecast (FY)₹42.54B
Bulls Say, Bears Say
Bulls Say
Improving Revenue And MarginsThe return to steady revenue growth after 2023, combined with materially stronger 2026 margins, indicates improving operating performance. If maintained, this mix of top-line recovery and operating leverage can support more durable earnings growth and strengthen the company’s ability to reinvest in its branded portfolio.
Minimal LeverageVery low leverage reduces interest and refinancing pressure while preserving capacity to fund products, commercial investment, or other strategic needs internally. A conservative capital structure also gives the company greater resilience if pharmaceutical demand, profitability, or operating cash flows become less predictable.
High-quality Free Cash FlowFree cash flow that closely tracks net income supports the quality of reported profits and indicates that earnings are generally being converted into usable cash. This provides a durable foundation for reinvestment and shareholder returns, subject to the reported variability in operating cash conversion.
Bears Say
Interrupted Revenue TrajectoryThe 2023 revenue decline shows that the company’s top-line progression has not been uninterrupted. Although growth subsequently reaccelerated, the prior contraction raises the need for continued execution across its product portfolio and distribution channels to establish a consistently durable growth trajectory.
Uneven Operating Cash ConversionVariability in operating cash flow conversion can make liquidity generation less predictable than reported earnings, even when overall free cash flow remains strong. Repeated timing or working-capital swings could complicate budgeting, reduce visibility into internally funded investment, and make annual cash performance more uneven.
Balance-sheet VolatilityThe sharp contraction in equity and total assets during 2022–2023 indicates that the capital base has not been completely stable over the period. Although rebuilding is a positive sign, such volatility warrants monitoring because it can affect the consistency of reported returns and financial planning.
GlaxoSmithKline Pharmaceuticals Limited News
GLAXO FAQ
What was GlaxoSmithKline Pharmaceuticals Limited’s price range in the past 12 months?
GlaxoSmithKline Pharmaceuticals Limited lowest stock price was ₹2088.00 and its highest was ₹3121.10 in the past 12 months.
What is GlaxoSmithKline Pharmaceuticals Limited’s market cap?
GlaxoSmithKline Pharmaceuticals Limited’s market cap is ₹420.73B.
When is GlaxoSmithKline Pharmaceuticals Limited’s upcoming earnings report date?
GlaxoSmithKline Pharmaceuticals Limited’s upcoming earnings report date is Nov 03, 2026 which is in 2 days.
How were GlaxoSmithKline Pharmaceuticals Limited’s earnings last quarter?
GlaxoSmithKline Pharmaceuticals Limited released its earnings results on Aug 03, 2026. The company reported ₹14 earnings per share for the quarter, beating the consensus estimate of ₹13.9 by ₹0.1.
Is GlaxoSmithKline Pharmaceuticals Limited overvalued?
According to Wall Street analysts GlaxoSmithKline Pharmaceuticals Limited’s price is currently Overvalued.
Does GlaxoSmithKline Pharmaceuticals Limited pay dividends?
GlaxoSmithKline Pharmaceuticals Limited pays a Annually dividend of ₹57 which represents an annual dividend yield of 2.29%. See more information on GlaxoSmithKline Pharmaceuticals Limited dividends here
What is GlaxoSmithKline Pharmaceuticals Limited’s EPS estimate?
GlaxoSmithKline Pharmaceuticals Limited’s EPS estimate is 16.5.
How many shares outstanding does GlaxoSmithKline Pharmaceuticals Limited have?
GlaxoSmithKline Pharmaceuticals Limited has 169,406,040 shares outstanding.
What happened to GlaxoSmithKline Pharmaceuticals Limited’s price movement after its last earnings report?
GlaxoSmithKline Pharmaceuticals Limited reported an EPS of ₹14 in its last earnings report, beating expectations of ₹13.9. Following the earnings report the stock price went up 0.141%.
Which hedge fund is a major shareholder of GlaxoSmithKline Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in IN:GLAXO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise, engages in the research, development, production, and global distribution of pharmaceutical drugs and vaccines. Its extensive product range encompasses both prescription and over-the-counter medications addressing diverse therapeutic areas such as anti-infectives, respiratory ailments, dermatology, nutritional deficiencies, gastrointestinal issues, and rare conditions. The company additionally provides consumer healthcare solutions. Prominent brands within its portfolio include Augmentin, Calpol, Ceftum, Eltroxin, Neosporin, Betnovate, Infanrix Hexa, Synflorix, and Boostrix, among numerous others. Founded in 1924 and headquartered in Mumbai, India, the company adopted its current name in 2001, having previously operated as SmithKline Beecham Pharmaceuticals India Ltd.
Technical Analysis
Abbott India Limited
―
Cipla Ltd
―
Gland Pharma Ltd.
―
PFIZER LIMITED
―
Sanofi Consumer Healthcare India Limited
―